Harvard Bioscience's total assets for Q1 2026 were $77.94M, a decrease of -2.66% from the previous quarter. HBIO total liabilities were $67.89M for the fiscal quarter, a 2.34% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.